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SUMMARY
Anti-Wolbachia therapy delivers safe macroﬁlaricidal activity with superior therapeutic outcomes compared to all standard
anti-ﬁlarial treatments, with the added beneﬁt of substantial improvements in clinical pathology. These outcomes can be
achieved, in principle, with existing registered drugs, e.g. doxycycline, that are aﬀordable, available to endemic
communities and have well known, albeit population-limiting, safety proﬁles. The key barriers to using doxycycline as an
mass drug administration (MDA) strategy for widespread community-based control are the logistics of a relatively lengthy
course of treatment (4–6 weeks) and contraindications in children under eight years and pregnancy. Therefore, the primary
goal of the anti-Wolbachia (A·WOL) consortium is to ﬁnd drugs and regimens that reduce the period of treatment
from weeks to days (7 days or less), and to ﬁnd drugs which would be safe in excluded target populations (pregnancy
and children). A secondary goal is to reﬁne regimens of existing antibiotics suitable for a more restricted use, prior to
the availability of a regimen that is compatible with MDA usage. For example, for use in the event of the emergence of
drug-resistance, in individuals with high loiasis co-infection and at risk of severe adverse events (SAE) to ivermectin, or in
post-MDA ‘endgame scenarios’, where test and treat strategies become more cost eﬀective and deliverable.
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INTRODUCTION
Filariasis continues to inﬂict serious public health
problems throughout tropical communities. The
major disease-causing species include those respon-
sible for lymphatic ﬁlariasis (LF), Wuchereria
bancrofti and Brugia malayi, and onchocerciasis,
Onchocerca volvulus, which together infect more
than 150 million people, ranking ﬁlariasis as one of
the leading causes of global morbidity (Taylor et al.
2010).
Global programmes for control and elimination
have been developed to provide sustained delivery of
drugs to aﬀected communities in order to interrupt
transmission of disease and ultimately eliminate this
public health burden (Amazigo, 2008; Sauerbrey,
2008; WHO, 2010). Currently used drugs, diethyl-
carbamazine/albendazole or ivermectin/albendazole
for LF and ivermectin (IVM) for onchocerciasis,
principally target the microﬁlarial stage of the
parasites and so require sustained and prolonged
delivery with high treatment coverage to endemic
communities in order to break the transmission cycle
of the long-lived adult worms (O. volvulus, 10–14
years; W. bancrofti/B. malayi, 5–8 years). The
impressive impact of these MDA programmes on
public health is well documented (Chu et al. 2010;
Coﬀeng et al. 2013), yet important challenges re-
main as these programmes translate from control
to elimination goals (Bockarie and Deb, 2010;
Mackenzie et al. 2012). Seventeen countries in hard-
to-reach areas, including post-conﬂict countries,
have still not implemented mass drug administra-
tion (MDA) against LF 12 years after the GPELF
was launched. In some of these countries, interrup-
tion of transmission will not be achieved using
the current strategy alone. The growing evidence
for resistance to IVM (Taylor et al. 2009; Osei-
Atweneboana et al. 2011) and safety constraints in
areas co-endemic with Loa loa (Scientiﬁc Working
Group on Serious Adverse Events in Loa Loa
endemic area, 2003) has re-focused the need and
urgency for new safe macroﬁlaricidal drugs and
regimens to achieve elimination goals within existing
timeframes (WHO, 2012).
Anti-Wolbachia therapy delivers safe macroﬁlar-
icidal activity with superior therapeutic outcomes
compared to all standard anti-ﬁlarial treatments, with
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the added beneﬁt of substantial improvements in
clinical pathology (Taylor et al. 2010; Tamarozzi
et al. 2011). These outcomes can be achieved, in
principle, with existing registered drugs, e.g. doxy-
cycline, that are aﬀordable, available to endemic
communities and have well known, albeit popu-
lation-limiting, safety proﬁles. Anti-Wolbachia
therapy delivers an early block in embryogenesis
and gradual macroﬁlaricidal activity leading to a
progressive and sustained elimination of microﬁlarial
load, thus avoiding the risk of SAE from target
species and those due to co-infections with L. loa
(a species without Wolbachia) (Taylor et al. 2005).
The use of doxycycline as a macroﬁlaricidal therapy
has been established as proof-of-concept in an
extensive series of ﬁeld trials (reviewed in Hoerauf,
2008; Taylor et al. 2010), but its widespread use
in community-based control is constrained by the
logistics of a relatively lengthy course of treatment
(4–6 weeks) and contraindications in children under
eight years and pregnancy. These barriers stimulated
the formation of the ‘Anti-Wolbachia’ (A·WOL)
consortium in 2007, which was funded by the Bill
& Melinda Gates Foundation to search for new
drugs active against Wolbachia that are suitable for
community-directed MDA with a secondary goal to
optimize regimens of existing drugs and re-purposed
registered drugs for use in more restricted target
populations (http://www.a-wol.net).
A ·WOL ASSAY DEVELOPMENT
Screening funnel
As a starting point, A·WOL developed a whole
organism Wolbachia cell-based assay as the primary
in vitro drug-screening tool. This validated assay,
which has been adapted to automated high through-
put-screening and represents a rapid, sensitive and
eﬃcient assay for screening chemical libraries,
utilizes a Wolbachia-containing Aedes albopictus cell
line (C6/36 Wp) (Turner et al. 2006), in a 96-well
format, with a quantitative PCR (qPCR) read-out to
quantify theWolbachia 16S rRNA gene copy number
following treatment (Johnston et al. 2010). Hits
from this primary in vitro cell-based screening
assay are selected based on their log drop depletion
of Wolbachia, reproducibility and, if using known
drugs, the target product proﬁle (TPP) as deﬁned by
A·WOL to include oral formulation, and the safe use
in children and pregnancy. These selected hits are
then moved down the screening pipeline into both
in vitro and in vivo nematode screening. In vitro
nematode screening, using either adult male
Onchocerca gutturosa (Townson et al. 2006) or adult
B. malayi, is intended to verify that hits are eﬀective
against nematode Wolbachia. These in vitro screens
also identify compounds that have no direct anti-
nematode activity yet show signiﬁcant reductions in
Wolbachia load. For in vivo nematode screening,
established animal models of ﬁlarial infection are
utilized and include Litomosoides sigmodontis in
mice (Hoerauf et al. 1999) and B. malayi in gerbils
(Ash and Riley, 1970). For all in vivo models, the
reduction of Wolbachia load following treatment is
measured by qPCR. The primary in vivo screening
model with L. sigmodontis allows for rapid screening
of compounds and yields a visible and quantiﬁable
phenotype of larvae with retarded growth. The
secondary in vivo model with B. malayi uses a
human ﬁlarial nematode and evaluates reductions
in Wolbachia load predictive of macroﬁlaricidal
activity, eﬀects on female fertility and microﬁlarial
production (Fig. 1).
Increasing the throughput and capacity of the
cell-based assay
To date, 558000 compounds have been procured
from multiple sources with *18000 having com-
pleted screening in our standard cell-based assay with
a qPCR read-out. In order to increase throughput
and capacity of the A·WOL cell-based screen we
have developed a 384-well format assay using a high
content imaging system (Operetta) and optimization
of growth dynamics in the C6/36 A. albopictus
mosquito cell-line. This assay uses texture analysis
of cells stained with Syto-11 as a direct measure of
bacterial load and enables a shorter screening period
and dramatically increases throughput and capacity.
The assay has completed validation against ‘hits’
identiﬁed using the standard qPCR assay and is
being used to complete diversity library screening
within a 10-fold increase in throughput (Taylor et al.
unpublished results).
A ·WOL LIBRARY SCREENING
One of the ﬁrst activities was to develop a TPP for
an A·WOL macroﬁlaricide. A·WOL worked with
consultants from the pharma industry to compile
four TPPs. Each TPP covered individual drug
Fig. 1. Screening funnel developed for A·WOL.
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administration (IDA) or MDA for either onchocer-
ciasis or LF. The screening campaign started with a
library of registered drugs and developed to include
focused libraries from pharma collaborators and large
diversity-based compound libraries.
Registered drug library
Following the validation of the primary cell-based
screen, the ﬁrst priority was to screen approved
human drug-pharmacopeia for potential repurposing
for anti-Wolbachia activity. Repurposing or reposi-
tioning of drugs provides a less risky route to drug
discovery given that candidates will already have
well-known safety and pharmacokinetic proﬁles,
and could provide a cost- and time-eﬀective
strategy to identify a novel A·WOL therapeutic. By
screening 2664 compounds from the human drug-
pharmacopeia, this strategy identiﬁed 121 hits that
had anti-Wolbachia activity; 69 of these were orally
available from diﬀerent diverse drug categories, with
nine compounds being more potent than doxy-
cycline. Several drugs have progressed further along
the screening pipeline into in vitro nematode assays
and in vivo screening models. The most advanced
lead, minocycline has shown an increase in potency of
50% compared to doxycycline in the secondary in vivo
screen and has entered eﬃcacy trials in humans (see
Drug Regimen Reﬁnement, below; Taylor et al. un-
published results).
Combination treatment
Combinations of registered drug-screening
outputs were assayed in a doxycycline enhancer
assay using sub-optimal doxycycline (50 nM) plus
21 of the registered drug hits. These outcomes
were used to design an extensive series of combi-
nations of registered A·WOL drugs. These drugs
were tested in the primary in vivo screen in triple
and double combinations, with further regimen
reduction experiments to determine the shortest
period of treatment. The outcome of these exper-
iments showed that in this model, double or triple
combinations of registered A·WOL drugs could
reduce the period treatment to 7 days or less to
deliver equivalent eﬃcacy to a standard course of
doxycycline monotherapy (Specht et al. unpublished
results). This outcome proved that there is no
biological barrier to delivering anti-Wolbachia
therapy in shortened regimens that could meet the
primary goal of an A·WOL regimen compatible
with MDA.
Focused drug libraries
Focused anti-infective libraries have been sourced
from several pharmaceutical companies and include
near-to-market lead candidate drugs or drug
class derivatives which are selected from known and
bio-informatically predicted essential gene targets
(Holman et al. 2009, see A·WOL Target Discovery).
Focused anti-infective library screening has, thus far,
involved A·WOL in vitro screening of 3062 novel
compounds from ﬁve chemical libraries. To date this
has generated 184 diverse hit compounds, a number
of which have progressed further into the screening
funnel. Encouragingly, there is a good agreement
between the reduction in Wolbachia load in the cell-
based and O. gutturosa in vitro assays with no eﬀect
on worm motility. This suggests that the hits do
not directly aﬀect the nematode (and are, therefore,
predicted to avoid direct parasite-mediated adverse
events). Notably, the ability to identify hit com-
pounds from these focused libraries which are
eﬀective at reducing Wolbachia load and have
improved eﬃcacy over doxycycline, is highly sup-
portive of the long-term goal to identify A·WOL new
chemical entities (NCEs).
Lead series originating from diversity library screens
A screen of >10000 compounds from the BioFocus
library revealed compounds that showed signiﬁcant
anti-Wolbachia activity. Retesting of these hits
conﬁrmed the identity of 50 compounds as conﬁrmed
hits (hit rate 0·5%). Chemoinformatic analysis of
these 50 hits has been used to identify the best hit
series (consisting of *6 chemotypes) with the
potential to enter a medicinal chemistry ‘hit to lead’
and lead optimization development phase in the
A·WOL II Macroﬁlaricide Drug Discovery pro-
gramme. We have developed a rational medicinal
chemistry programme around each of the six hit
series. From the top six hits we have selected three
templates for hit to lead optimization with three
additional back-up templates. We are currently
running a head to head evaluation of the three series
with the intention of identifying the most promising
template for ﬁnal lead optimization.
Key outcomes from A·WOL library screening
include the development of a portfolio of drug
discovery projects with the potential to generate
at least one new anti-wolbachial chemotype for
eventual deployment as a macroﬁlaricide monother-
apy (although deployment in combination would
remain an option). Evidence to date suggests that
there is no biological barrier to a reduced curative
dosage regimen. We have already provided proof-
of-concept for this in experimental double/triple
combination studies. Furthermore the life-style con-
straints of Wolbachia make acquisition of plasmid-
based resistance mechanisms highly unlikely hence
reducing the risk of monotherapy-driven resist-
ance. To date several hundred ‘hits’ have been
identiﬁed and conﬁrmed from screening of focused
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libraries from pharma and large diversity-based
libraries (Table 1).
A ·WOL TARGET DISCOVERY
Targets of key enzymatic and metabolic pathways
predicted fromWolbachia genomic annotation
Annotation of the wBm genome suggestedWolbachia
might provide haem, ﬂavin adenine dinucleotide,
riboﬂavin and nucleotides to the B. malayi host,
which cannot synthesize these molecules de novo
(Foster et al. 2005; Slatko et al. 2010). For example,
two enzymes of thewBmhaem biosynthetic pathway,
ALAD (aminolevulinic acid dehydratase) and FeCH
(ferrochelatase), have been evaluated as candidate
targets based on their low conservation to the
corresponding human proteins, their distinct bio-
chemical properties and sensitivities to inhibitors
relative to the human enzymes. Inhibition of ALAD
with succinyl acetone resulted in reduced worm
motility in vitro (Wu et al. 2009) although FeCH is
present both in Wolbachia and in the nematode
genome through a lateral gene transfer event from
an unrelated α-proteobacterium (Wu et al. 2013).
Also, because ALAD is not found in the genome of
B. malayi and is signiﬁcantly diﬀerent from the
human orthologue, it was subjected to both aptamer-
and chemical library-screening as part of the A·WOL
programme.
Comparative genomic analyses and examination
of metabolic pathway maps can indicate key diﬀer-
ences between processes that are otherwise conserved
between Wolbachia and humans leading to the
identiﬁcation of additional potential drug targets in
Wolbachia. For example, the ﬁnal step in glycolysis is
catalysed by pyruvate kinase in humans but by a
distinct alternative enzyme, pyruvate phosphate
dikinase (PPDK), in Wolbachia (Raverdy et al.
2008). PPDK is not found in mammals. The
Wolbachia PPDK enzyme has also been included
in both aptamer-based and conventional library
screening as part of A·WOL.
wALAD. The Wolbachia ALAD protein involved
in the synthesis of haem was identiﬁed and validated
as a target for drug screening. Direct screening of a
small molecule library of 18000 compounds against
the enzyme assay identiﬁed 7 compounds that
inhibited wALAD compared to hALAD. Three of
the compounds were based on the same benzimida-
zole core structure. These clustered compounds also
had the highest andmost speciﬁc level of inhibition of
wALAD. For this reason, eﬀorts were focused on this
core structure and the best inhibitor now named
wALADin 1. Characterization of the inhibitory
activity has identiﬁed the mode of inhibition to be
a Mixed-Model Inhibition with a calculated KI of
11 μM. wALADin 1 was screened in the primary
cell-based assay, but unfortunately showed no
activity. Activity could be demonstrated against
nematodes in vitro, although only in the 0·25–
0·5 mM range (Lentz et al. 2013). Although this
work further validated haem biosynthesis as a target,
in view of the more potent and tractable hits
identiﬁed through library screening, further work
on wALADin 1 was suspended.
PPDK. The enzymatic assay for PPDK was
successfully modiﬁed for a micro-titre plate format
and produced acceptable Z’ values. This assay was
used to screen PPDK activity against the small
molecule library of 18000 compounds. Due to the
large number of hits, the threshold for our cut-oﬀ
for a hit was raised from 50% inhibition to 80%
inhibition. 22 compounds met or surpassed this cut-
oﬀ. This list was then shortened to 7 highly active
compounds that appeared to be speciﬁc for PPDK
(i.e. they did not inhibit wALAD). The two best
compounds were found to be non-speciﬁc, therefore
further development was suspended.
LspA. Lipoproteins are essential structural and
functional components of bacteria and those from
Wolbachia are potent stimulators of the innate and
adaptive inﬂammatory pathogenesis of ﬁlarial disease
(Turner et al. 2009; Tamarozzi et al. 2011). The
Wolbachia prolipoprotein signal peptidase II (LspA)
was shown to be functional and the Wolbachia cell-
based assay and adult B. malayi were sensitive to
inhibition with a known LspA inhibitor, globomycin
(Johnston et al. 2010) validating LspA as an anti-
Wolbachia target.
The ‘essential gene set’ ofWolbachia
In order to target focused library screening to
drugs with predicted activity against Wolbachia, a
bioinformatic analysis of predicted essential genes
was undertaken. An essentiality score for each
predicted gene of wBm was determined by two
separate approaches (Holman et al. 2009). The ﬁrst
method compared each gene to entries in DEG (the
Database of Essential Genes), a collection of*5000
experimentally identiﬁed essential genes from 15
diﬀerent bacterial species, to predict essential genes
that aremostly conserved across the bacterial domain.
The second approach used phyletic conservation
across members of the order Rickettsiales, to which
Wolbachia belongs, in order to highlight genes that
are well conserved and thus likely to be essential.
Conservation of genes in these rickettsial genomes
that are undergoing reductive evolution underscores
their importance. A ranked essentiality list was
produced by each method and showed complemen-
tary and partially overlapping sets of wBm genes.
Many of the top-ranking genes fall into classes of
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Table 1. Summary of A·WOL screening campaign
Compound class
Screened
in vitro
cell assay
Hits
in vitro
Hits conﬁrmed
using in vitro
worm
Hits
screened
in 1° in vivo
Active (5doxy)
in 1° in vivo
Hits screened
in 2° in vivo
Active (5doxy)
in 2° in vivo
Phase II trials
in Ghana
Repurposing
or lead
optimization
series
Registered drug screening
Registered drugs 2664 69 3 20 4 2 1 Minocycline
Registered drugs 80 4 3 0
Total 2744 73 23 4 2 1 1
Focused library screening
Tetracyclines 1084 96 3 82 19
Boron based 2744 179 3 2 Ongoing 2 Ongoing 3
Quinolones, macrolides, NRIs 312 99 3 5 1 1 1 3
Antibacterials, kinase inhibitors 409 62 16 6 3
Active against Mtb 1477 22
Novel quinolones 350 21 Ongoing 3
Epichem-fenarimol series 50 4
Antibacterials, anti-Mtb 1128 97
Total 7554 580 105 26 3 1
3
Soft-focus diversity 9946 112 Ongoing
Natural products 2400 15
DOS library 924 2
Diversity 500000 Ongoing
Diversity 15000 TBA
Diversity 150000 TBA
Total 678270 129 nd nd nd nd
Grand total 688568 782 128 30 5 2 1
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genes targeted by current antibiotics and are in
functional categories predicted to be essential for
bacterial growth. The high essentiality prediction of
such known targets validates the computational
approach. The ranked lists can be further curated to
prioritize candidate drug targets by ﬁltering for genes
with no similarity to human proteins for example.
The druggability of the wBm proteins was addressed
by comparing them to known protein targets
contained within theDrugBank database, a collection
of *5000 FDA-approved small molecule drugs and
compounds with details of their protein-binding
partners and relevant chemical and pharmacological
data. This analysis correlated well with the essential
gene predictions and revealed classes of wBm
proteins that appear to be essential and druggable
(Holman et al. 2009).
Screening of focused libraries generated with
reference to the predicted essential gene list has
delivered several lead compounds/drugs, which are
undergoing further evaluation in A·WOL II
Macroﬁlaricide Drug Discovery and A·WOL II
Macroﬁlaricide Drug Development programmes.
Further insight into the biological basis of
Wolbachia symbiosis
A deeper understanding of the nature of the
symbiotic relationship between Wolbachia and its
ﬁlarial host and the consequences of Wolbachia
depletion on the biology of the nematode has
advanced in recent years (Taylor et al. 2012). It
now appears that the dependency of the nematode–
Wolbachia relationship is most critical during periods
of high metabolic demands, such as larval develop-
ment, growth and fertility, processes that coincide
with periods of rapid Wolbachia population growth
and expansion (McGarry et al. 2004; Taylor et al.
2012).
Why doesWolbachia depletion induce
anti-ﬁlarial activity?
Studies on the cellular consequences of symbiont
elimination have provided an important insight into
the cellular mechanisms at the basis of the symbiotic
relationship (Landmann et al. 2011). Soon after
antibiotic elimination of the bacteria extensive
apoptosis occurs in the adult germline and in the
somatic cells of the embryos, microﬁlariae and
fourth-stage larvae (L4). Apoptosis extends to unin-
fected cells, suggesting an indirect provision of
products from the hypodermal population is required
to prevent cells from undergoing cell death. This
cellular mechanism does not extend to all somatic
cells, including those of the hypodermal cord cells,
where the bacteria reside, although the cytoskeletal
arrangement is disrupted. The pattern of apoptosis
activation correlates closely with the stages most
vulnerable to antibiotic depletion and provides a
mechanism to account for the rapid anti-ﬁlarial
eﬀects of antibiotic treatment. Additionally apoptosis
signals in host nematodes could serve as useful
biomarkers of anti-Wolbachia activity.
Wolbachia populations are regulated by autophagy
and autophagy-inducing drugs deliver bactericidal
activity
In order to understand the process by which the
host nematode regulates the population growth of
Wolbachia at a suﬃcient level to maintain the
symbiosis, yet to avoid ﬁtness costs or the patho-
logical consequences of bacterial overgrowth, we
investigated the role of autophagy, a conserved
intracellular defence mechanism and regulator of
cell homeostasis (Voronin et al. 2012). Activation of
autophagy coincided with the onset of rapid bacterial
growth and expansion, which shows that, in spite of
their mutualistic association, the nematode’s immune
system recognisesWolbachia as a ‘pathogen’. Genetic
and chemical modulation of autophagy activation or
suppression resulted in a corresponding decrease or
increase in bacterial populations. To test whether
drugs which induce the activation of autophagy
could lead to a reduction in Wolbachia populations
in vivo, we treated jirds infected with B. malayi with
rapamycin and spermidine. Treatment with rapamy-
cin or spermidine reducedWolbachia loads by*70%
for both drugs compared to the control (Voronin
et al. 2012). These results provide proof-of-concept
that drug-induced activation of autophagy is eﬀective
at reducingWolbachia populations in vivo to the same
extent as antibiotic therapy and identiﬁes a novel
bactericidal mode-of-action which can be exploited
in the discovery and development of new anti-
Wolbachia treatments.
A ·WOL REGIMEN REFINEMENT
In order to address A·WOL’s second goal to
optimize regimens of known anti-wolbachial drugs
(doxycycline and rifampicin), we carried out a
series of phase II ﬁeld trials with the aim of testing
the eﬃcacy of reduced dosage (200 to 100mg) and to
test whether combinations of anti-wolbachial drugs
can reduce the treatment period. Two additional
studies were initiated to pilot the lead candidate
from our registered library screen (minocycline)
and to evaluate the eﬃcacy of community-directed
doxycycline treatment four years after delivery.
(1) A·WOL LF I: RCT phase II trial, doxycycline
vs doxycycline/rifampicin and doxycycline dose
reduction (200 to 100mg), Ghana. (2) A·WOL
oncho I: RCT phase II trial, doxycycline vs doxy-
cycline/rifampicin and doxycycline dose reduction
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(200 to 100mg), Ghana. (3) A·WOL oncho II:
Open label pilot trial, doxycycline vs minocycline±
albendazole, Ghana. (4) A·WOL oncho III:
Evaluation of the eﬀectiveness of community-
directed delivery of doxycycline four years after
delivery (Cameroon).
All follow-up sampling of phase II and pilot trials
is now complete, with ongoing laboratory analysis of
primary and secondary endpoints underway, which is
expected to be completed by the end of 2013.
In 2007 and 2008, a feasibility trial of community-
directed treatment with doxycycline was carried out
in two health districts in Cameroon, co-endemic for
O. volvulus andL. loa (Wanji et al. 2009).With 17 519
eligible subjects, the therapeutic coverage was 73·8%
with 97·5% compliance, encouraging the feasibility of
using doxycycline community-directed delivery in
restricted populations of this size. The eﬀectiveness
of this community-directed delivery of doxycycline
was further evaluated four years after delivery
(Tamarozzi et al. 2012). Statistically signiﬁcant
lower microﬁlarial prevalence (17·0% [doxycycline
plus ivermectin group], 27·0% [ivermectin only
group], P = 0·014) and load (P = 0·012) were
found in people that had received doxycycline
followed by ivermectin compared to those who
received ivermectin only. This study demonstrates
the long-term eﬀectiveness of doxycycline treatment
delivered with a community-directed strategy even
when evaluated four years after delivery in an area of
ongoing transmission. This ﬁnding shows that a
multi-week course of treatment is not a barrier to
community-delivery of MDA in restricted popu-
lations of this size and supports its implementation to
complement existing control strategies for onchocer-
ciasis, where needed (Tamarozzi et al. 2012).
A ·WOL MATHEMATICAL MODELLING
An extensive series of trials has shown that
doxycycline treatment eliminates Wolbachia causing
long-term sterilization of adult female ﬁlariae and
ultimately exerting a macroﬁlaricidal eﬀect against
onchocerciasis and LF. Such trials have been
conducted in endemic settings where continual
reinfection by drug-naïve worms compromises the
evaluation of macroﬁlaricidal eﬃcacy (Specht et al.
2009). This makes it diﬃcult to estimate therapeutic
eﬃcacy and compare data from diﬀerent doxycycline
regimens collected at diﬀerent times post-treatment.
A mathematical model was developed which couples
the doxycycline-induced depletion of Wolbachia
from adultO. volvulus to the ensuing macroﬁlaricidal
activity (Walker et al. unpublished results). The
model was ﬁtted to data from clinical trials measuring
the Wolbachia status and viability of individual
female adult worms exposed to a 4-, 5- or 6-week
daily dose of 100 or 200mg oral doxycycline.
Doxycycline induces rapid depletion of Wolbachia,
yet these eﬀects are most apparent 9·5 months after
the start of treatment. The estimated therapeutic
eﬃcacy of doxycycline in eliminatingWolbachia from
female O. volvulus increases statistically signiﬁcantly
from 92 to 95% from 4 to 5 weeks of treatment and
non-signiﬁcantly from 95 to 97% from 5 to 6 weeks
of treatment, irrespective of dose. This model
validates the marked macroﬁlaricidal activity of
doxycycline therapy and provides robust statistical
support for equivalent eﬃcacy with reduced time-
frames and dosage and can be adapted to the analysis
of other A·WOL therapies for the treatment of both
onchocerciasis and LF.
ANTI -WOLBACHIA TREATMENT IMPROVES
CLINICAL DISEASE
Previously, a course of doxycycline was shown not
only to possess macroﬁlaricidal activity, but also lead
to signiﬁcant clinical improvements in the severity
of lymphoedema (Debrah et al. 2006). In a second
trial this outcome was compared with a course of
amoxicillin and in patients without active LF
infection (Mand et al. 2012). Doxycycline-treated
patients with lymphoedema (LE) stage 2–3 showed
signiﬁcant reductions in LE severity after 12 and
24 months, regardless of circulating ﬁlarial antigen
status. Improvement was observed in 43·9% of
doxycycline-treated patients, compared with only
3·2 and 5·6% in the amoxicillin and placebo arms,
respectively. Both doxycycline and amoxicillin re-
duced acute dermatolymphangioadenitis attacks.
This unexpected outcome showed that improve-
ments in lymphoedema were also found in patients
without active infection, which expands the use of
this approach as a new and improved tool for
morbidity management as part of GPELF (Mand
et al. 2012).
CONCLUSIONS
A·WOL has developed a series of validated and
robust assays to evaluate drugs and compounds
with anti-Wolbachia activity which have been used
to screen a range of registered, focused and diversity
drug libraries to deliver several hundred ‘hits’,
which are progressing through the screening
funnel with the potential to generate at least one new
anti-wolbachial chemotype for eventual deployment
as a macroﬁlaricide. The outcomes of the initial
A·WOLprogrammeareprogressing throughA·WOL
II Macroﬁlaricide Drug Discovery and A·WOL II
Macroﬁlaricide Drug Development programmes.
Regimens of known A·WOL drugs have been
optimised for dosage and time-frame to deliver a
curative course of treatment equivalent to regimens
for prophylaxis for traveller’s malaria and acne which
can be considered, in restricted populations, to
complement existing MDA strategies in ‘hot spot’
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foci or residual populations in MDA end-game
scenarios, where test and treat strategies become
more cost-eﬀective and deliverable than MDA.
An example is the decision by Onchocerciasis
Elimination Programme for the Americas (OEPA)
to use doxycycline in attempts to foreshorten the time
to elimination in a focus in Venezuela to achieve the
Regional Elimination goal. The WHO Road Map
(WHO, 2012) at the time of the commitment to the
London Declaration on NTDs has ambitious targets
based on existing available preventive chemotherapy
tools. However, it is recognized that if there is to
be a more rapid drive towards elimination and
strategies to tackle the barriers of reduced eﬃcacy
of existing drugs and L. Loa, A·WOL outcomes
should be considered for deployment at the earliest
opportunity.
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